REGENXBIO Inc. (NASDAQ:RGNX) is set to release its earnings data before the market opens on Wednesday, November 8th. Analysts expect REGENXBIO to post earnings of ($0.73) per share for the quarter.
REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.34. REGENXBIO had a negative net margin of 839.87% and a negative return on equity of 38.74%. The firm had revenue of $6.56 million during the quarter. On average, analysts expect REGENXBIO to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
REGENXBIO Inc. (NASDAQ RGNX) opened at $28.80 on Monday. REGENXBIO Inc. has a 1-year low of $16.00 and a 1-year high of $36.10.
ILLEGAL ACTIVITY WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2017/11/06/regenxbio-inc-rgnx-to-release-earnings-on-wednesday.html.
In related news, insider Kenneth T. Mills sold 6,500 shares of the firm’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $20.05, for a total transaction of $130,325.00. Following the transaction, the insider now directly owns 105,500 shares of the company’s stock, valued at $2,115,275. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Vittal Vasista sold 3,040 shares of the stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $21.09, for a total transaction of $64,113.60. Following the sale, the chief financial officer now owns 103,118 shares in the company, valued at $2,174,758.62. The disclosure for this sale can be found here. Insiders sold 210,040 shares of company stock worth $5,874,639 over the last three months. Insiders own 17.00% of the company’s stock.
RGNX has been the subject of several research analyst reports. Chardan Capital increased their target price on shares of REGENXBIO from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, August 9th. Zacks Investment Research raised shares of REGENXBIO from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research report on Saturday, August 12th. BidaskClub raised shares of REGENXBIO from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. Evercore ISI initiated coverage on shares of REGENXBIO in a research report on Wednesday, August 16th. They set an “outperform” rating and a $25.00 price target on the stock. Finally, Bank of America Corporation upped their price target on shares of REGENXBIO from $29.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, September 21st. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $40.00.
REGENXBIO Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
What are top analysts saying about REGENXBIO Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for REGENXBIO Inc. and related companies.